

## Research Article

## Comparison of Retinal Nerve Fiber Layer Thickness Changes after Intravitreal Bevacizumab in Patients of Diabetic Macular Edema

Muhammad Shaheer<sup>1\*</sup>, Asad Aslam Khan<sup>2</sup>, Nasir Ahmed<sup>3</sup>, Tehseen Mahmood Mahju<sup>4</sup>, Ummarah Rasheed<sup>5</sup>

<sup>1</sup>Senior Registrar, Department of Ophthalmology, Lahore General Hospital, Lahore; <sup>2</sup>Professor & Dean Faculty of Ophthalmology KEMU/ Mayo Hospital, Lahore; <sup>3</sup>Assistant Professor of Ophthalmology, KEMU/ Mayo Hospital, Lahore; <sup>4</sup>Senior Registrar, Department of Ophthalmology, Mayo Hospital, Lahore; <sup>5</sup>Statistician, COAVS, KEMU, Lahore, Pakistan.

**Abstract** | Diabetic macular edema is one of the leading causes of visual loss in diabetic patients. However, the impact of medicinal treatment on the occurrence of macular edema remained elusive.

**Objectives:** This study was designed to determine the effect of intravitreal bevacizumab in patients of diabetic macular edema.

**Methods:** An interventional study was conducted on patients that underwent pre-injection and one-month post-injection OCT for RNFL thickness. OCT was performed by researchers and findings were recorded accordingly. The retinal nerve fiber layer thickness was measured in superior, inferior halves and total average thickness. Pre- and post-injection OCT were conducted and macular thickness were documented.

**Results:** The mean retinal nerve fiber layer thickness was decreased in superior and inferior halves as well as in the total thickness.

**Conclusion:** Intra vitreal bevacizumab decreases the retinal nerve fiber layer thickness. Large randomized controlled trials are required to establish or rule out any association between this decrease in thickness and incidence of glaucoma in such patients.

**Received** | August 02, 2017; **Accepted** | January 10, 2018; **Published** | March 31, 2018

**\*Correspondence** | Dr. Muhammad Shaheer, Senior Registrar, Department of Ophthalmology, Lahore General Hospital, Lahore; **Email:** mshaheer212@gmail.com

**Citation** | Shaheer, M., A.A. Khan, N. Ahmed, T.M. Mahju, U. Rasheed. 2018. Comparison of retinal nerve fiber layer thickness changes after intravitreal bevacizumab in patients of diabetic macular edema. *Annals of King Edward Medical University*, 24(1): 44-48.

**DOI** | <https://doi.org/10.21649/akemu.v24i1.2320>

**Keywords** | Diabetic macular edema, Retinal nerve fiber layer thickness, OCT.

### Introduction

Intra vitreal administration of drugs has become a popular mode of treatment of various vitreoretinal disorders including diabetic macular edema, proliferative diabetic retinopathy, and viral infections of posterior segment<sup>(1, 2, 3)</sup>. Diabetes mellitus is one of the most prevalent metabolic diseases, which affect the eye within years and if the blood sugar level is not kept under control then it can lead to a blind eye within years. Most common ocular involvement of the eye in diabetes is that of retinal vessels classified

as diabetic retinopathy and one of the features of diabetic retinopathy is macular edema<sup>(4, 5)</sup>. Now a days the most prevalent treatment option for diabetic macular edema is intra vitreal anti VEGF injections<sup>(6)</sup>. In Pakistan, the most commonly used anti-VEGF agent is bevacizumab also known as Avastin. The Bevacizumab is a monoclonal anti body which is injected into the vitreous cavity through pars plana. The duration of action of single injection is around four weeks after which it has to be repeated if indicated. Intra vitreal anti VEGF agents reduce the permeability of vessels in addition to helping in absorption of already

present fluid within the retinal layers<sup>(7)</sup>. Retinal nerve fiber layer is an important layer of retina in relation to the development of glaucoma. This is the layer which is affected when the glaucomatous damage occurs due to raised IOP<sup>(8,9)</sup>. So the diseases which affect the retina i.e. diabetes may also affect this layer particularly<sup>(10)</sup>. Also during the treatment of various retinal diseases, anatomy of this layer may be changed thereby rendering it more susceptible to glaucomatous damage. Literature shows that surgery of the posterior segment does affect the thickness of RNFL as do the intra vitreal injections.

### Materials and Methods

It was a quasi-experimental study and all patients (n=64) presented during the study period of one year fulfilling the inclusion and exclusion criteria were considered. The patients diagnosed with diabetic macular edema on fundus examination were included in study. The patients diagnosed with any other macular edema, retinal disease or any coexisting ocular disease were excluded from study. Informed consent was obtained from all the patients and the procedure was explained to them. Pre injection retinal nerve fiber layer thickness was measured on OCT and recorded on proforma. All the patients were administered intra vitreal bevacizumab 1.25mg/0.05ml injection.

After aseptic measures, a point was identified in the supero temporal quadrant of the globe which was about 4mm from limbus. The measurement was performed with the help of calipers. From that point, the needle entry was made and bevacizumab was administered into vitreous cavity. After that needle was withdrawn and the site of entry was held pressed with a corneal forceps in order to prevent any reflux of drug from the entry site. The eye was then cleaned and pad was applied. Post operatively antibiotic drops were prescribed for a period of one week. All the patients were called on next day for anterior and posterior segment examination. The patients were followed

at one month for RNFL thickness measurement. The OCT was conducted by the researcher and findings were recorded. The data was entered in SPSS and independent sample t-test was applied for the comparison of pre and post injection thickness.

### Results

Out of the 64 patients, 30 were male and 34 were female. The mean age of male patients was 55.71±4.16 and in female patients it was 55.93±4.14. In the operated eye mean Pre injection superior RNFL thickness was 95.28±5.43 and in the non-operated eye mean pre injection superior RNFL thickness was 94.93±5.08. In the operated eye mean post injection superior RNFL thickness was 94.06±5.03 and in the non-operated eye the mean post injection superior RNFL thickness was 94.63±4.97. The mean change in superior RNFL thickness in operated eye was 1.21±1.45 while it was 0.30±0.62 in the non-operated eye (p 0.0001).

In the operated eye mean pre injection inferior RNFL thickness was 96.17±4.73 and in the non-operated eye mean pre injection inferior RNFL thickness was 94.42±3.67. In the operated eye mean Post injection inferior RNFL thickness was 94.90±4.40 and in the non-operated eye the mean post injection inferior RNFL thickness was 93.58±3.57. The mean change in inferior RNFL thickness in operated eye was 1.27±1.87 while it was 0.84±0.95 in the non-operated eye (p 0.0001) (Table 1).

In the operated eye mean pre injection total RNFL thickness was 95.73±4.21 and in the non-operated eye mean pre injection total RNFL thickness was 94.66±3.31. In the operated eye mean post injection total RNFL thickness was 94.34±4.27 and in the non-operated eye the mean post injection total RNFL thickness was 94.10±3.19. The mean change in total RNFL thickness in operated eye was 1.38±1.76 while it was 0.56±0.57 (p 0.0001) (Table 2).

**Table 1: Changes in RNFL thickness in superior and inferior quadrants**

Sr No	RNFL thickness	Superior		Inferior	
		Operated eye	Non operated eye	Operated eye	Non operated eye
1	Pre injection	95.28±5.43	94.93±5.08	96.17±4.73	94.42±3.67
2	Post injection	94.06±5.03	94.63±4.97	94.90±4.40	93.58±3.57
3	Change in thickness	1.21±1.45	0.30±0.62	1.27±1.87	0.84±0.95

p value 0.0001 (Operated eye)

In the operated eye mean central macular thickness pre injection was 512.12±89.28 microns while post injection it was 429.03±72.94 microns. In the non-operated eye mean central macular thickness pre injection was 215.34±8.16 microns while it was 214.60±7.91 microns. The mean difference in macular thickness in the operated eye was 83.09±36.90 microns while in the non-operated eye it was 0.73±1.75 microns (Table 3).

**Table 2:** Total changes in rnfl thickness after intravitreal avastin

Sr No	Change in RNFL thickness	Total thickness	
		Operated eye	Non operated eye
1	Pre injection	95.73±4.21	94.66±3.31
2	Post injection	94.34±4.27	94.10±3.19
3	Change in thickness	1.38±1.76	0.56±0.57

*P 0.0001 (Operated eye)*

**Table 3:** Changes in macular thickness in both eyes

Sr No	Macular thickness	Eye	
		Operated eye	Non-operated eye
1	Pre injection	512.12±89.28	215.34±8.16
2	Post injection	429.03±72.94	214.60±7.91
3	Change in thickness	83.09±36.90	0.73±1.75

## Discussion

This research had found the changes in RNFL thickness after one injection of intravitreal bevacizumab for diabetic macular edema. It is well known that posterior segment surgery or pan retinal photocoagulation alter the thickness of retinal nerve fiber layer. But very few studies have been performed to study the effect of various intravitreal injections on RNFL thickness. In this study the results showed that RNFL thickness was decreased in superior and inferior halves in addition to a decrease in total average thickness. The authors also compared the changes in RNFL thickness in the fellow eye before and after intravitreal bevacizumab injection. The study showed that the RNFL thickness was decreased in all the quadrants and the decrease in RNFL thickness was symmetrical in both the superior and inferior halves of the operated eye. The non-operated eye also showed symmetrical decrease in RNFL thickness. None of the patient was diagnosed with glaucoma during the follow up period.

Intra vitreal anti VEGF injection as a very convenient outpatient procedure. After aseptic measures the injection is administered in the vitreous cavity, the eye is padded and the patient can go home immediately after the procedure. Other researchers had reported similar findings. El-Ashry M et al<sup>(11)</sup> have studied changes in RNFL thickness in twenty four patients after phacoemulsification with intra ocular implant. The mean pre-operative RNFL thickness was 84.9±16.5 while the mean post-operative RNFL thickness was 93.0±17.6. So in their study cataract extraction increased the RNFL thickness which was clinically significant.

Aydin A et al<sup>(12)</sup> have studied RNFL thickness changes after trabeculectomy. They documented an increase of 0.5µm/mm reduction of intraocular pressure. So they concluded that 30 % IOP reduction as a result of trabeculectomy leads to an increase in RNFL thickness.

Pareja-Esteban J et al<sup>(13)</sup> have studied RNFL changes after cataract extraction. The mean pre-operative RNFL thickness was 90.71±19.93 while post-operative RNFL thickness after one day was 88.30±20.59 and at one month it was 97.45±14.30 microns. The results were not statistically significant.

Demntyev DD et al<sup>(14)</sup> have studied changes in RNFL thickness after LASIK. In their study, mean pre-operative thickness was 104.2±9.0 while mean post-operative thickness after one week was 101.9±6.9 and at three months it was 106.7±6.1. The changes in RNFL thickness were statistically insignificant.

Yamashita T et al<sup>(15)</sup> have analyzed changes in RNFL thickness in patients presenting with or without visual field effects after pars plana vitrectomy and internal limiting membrane peeling aided with indocyanin green. The concluded that the RNFL thickness decreased more in patients with defects in the visual field as compared to the patients who did not develop any visual field defects.

Young-Joon J et al<sup>(16)</sup> have studied changes in RNFL thickness after intra vitreal anti VEGF therapy in 20 patients. They concluded that the average total RNFL thickness decreased from 98±6.8 to 96.3±4.2 after six months of anti VEGF therapy. This thickness in the inferior zone decreased from 120.9±10.1 to 120.7±9.3 and the thickness in the superior zone decreased from

122.8±10.2 to 121.8±6.5. This decrease in the RNFL thickness was clinically and statistically insignificant.

Hatata RM et al<sup>(17)</sup> have studied changes in RNFL thickness after intravitreal triamcinolone acetonide in patients of macular edema. In their study mean average RNFL thickness changes from 91.63±10.5 to 90.83±10.11. The mean superior RNFL thickness decreased from 104.57±15.3 to 103.08±15.3. The mean inferior RNFL thickness changed from 118.9±19.95 to 111.8±19.95. The decrease in RNFL thickness was clinically and statistically insignificant.

Martinez JM et al<sup>(18)</sup> have studied the RNFL thickness changes after multiple injections of intravitreal Ranibizumab in patients of wet age related macular degeneration. In their study significant retinal nerve fiber layer thinning was observed. Base line RNFL thickness was 105.7±12.2 which significantly reduced to 100.2±11.0 after twelve months.

During literature search various studies were found which showed that RNFL thickness increased after vitreo retinal surgery but no study was found which concluded an increase in RNFL thickness after intravitreal bevacizumab. Lee YH et al<sup>(19)</sup> studied the RNFL thickness changes after Pars Plana vitrectomy to achieve retinal reattachment. In their study the RNFL thickness pre-operatively was 120.7±13.5 which was increased post-operatively i.e. 124.7±24.5 at six months, 124.0±16.6 at twelve months and 123.8±14.3 at twenty four months. This increase in RNFL thickness was significant.

Lee SB et al<sup>(20)</sup> have studied retinal nerve fiber layer changes after pars plana vitrectomy for epiretinal membrane. Their comparison between the involved and non-involved eye showed that the mean RNFL thickness was increased at baseline (112.88±12.66 & 102.94±11.58) and at 1 month (112.63±15.43 & 102.95±11.49) but decreased at 12 months (94.47±13.53 & 103.57±9.0).

Entazari M et al<sup>(21)</sup> studied RNFL thickness changes after two intra vitreal bevacizumab injections for neovascular age related macular degeneration. They studied RNFL thickness changes in all four quadrants at week 12 and 24 post injection. In their study the RNFL thickness was reduced from baseline at 24 weeks except for the inferior quadrant in which it was increased.

## Conclusions

In our study the mean RNFL thickness decreased after treatment with intravitreal bevacizumab in patients of diabetic macular edema.

## Author's Contribution

**Muhammad Shaheer:** Conceived and designed the study, collected the data and wrote the article.

**Asad Aslam Khan:** Supervised the research, reviewed the manuscript and drafted the intellectual content.

**Nasir Ahmed and Tehseen Mahmood Mahju:** Diagnosis and selection of patients and administering the intravitreal injection.

**Ummarah Rasheed:** Performed statistical analysis.

## References

1. Lee K, Jung H, Sohn J. Comparison of injection of intravitreal drugs with standard care in macular edema secondary to branch retinal vein occlusion. *Korean Journal of Ophthalmology*. 2014; 28(1):19-25. <https://doi.org/10.3341/kjo.2014.28.1.19>
2. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib and bevacizumab. *Eye*. 2009; 23:181-185. <https://doi.org/10.1038/sj.eye.6702938>
3. Kim H, Lizak MJ, Tansey G, Csaky KG, Robinson MR, Yuan P, Wang NS. *Annals of Biomedical Engineering*. 2005; 33(2):150:164.
4. Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Parajasegaram R, Verdaguer JT. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. *Ophthalmology*. 2003; 110(9):1677-1682. [https://doi.org/10.1016/S0161-6420\(03\)00475-5](https://doi.org/10.1016/S0161-6420(03)00475-5)
5. Kempen JH, O'Colmain BJ, Leske MC, Haffner HM, Klein R, Moss SE, Taylor HR, Hamman RF. The prevalence of diabetic retinopathy among adults in the United States. *Archives of Ophthalmology*. 2004; 122(4):552-563. <https://doi.org/10.1001/archophth.122.4.552>
6. Arevalo JF, Fromow-Guerra J, Quieroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: Results from the Pan-American collaborative retina study group

- at 6 months followup. *Ophthalmology*. 2007; 114(4):743-750. <https://doi.org/10.1016/j.ophtha.2006.12.028>
7. Mukherji SK. Bevacizumab (Avastin). *American journal of neuroradiology*. 2010; 31(2):235-236. <https://doi.org/10.3174/ajnr.A1987>
  8. Kanamori A, Nakamura M, Escano MFT, Seya R, Maeda H, Negi A. Evaluation of the glaucomatous damage on the retinal nerve fiber layer thickness measured by optical coherence tomography. *American Journal of Ophthalmology*. 2003; 135(4):5130520. [https://doi.org/10.1016/S0002-9394\(02\)02003-2](https://doi.org/10.1016/S0002-9394(02)02003-2)
  9. Medeiros FA, Zangwill LM, Bowd C, Vessani RM, Sussana RJ, Weinreb RN. Evaluation of retinal nerve fiber layer, optic nerve head and macular thickness measurements for glaucoma detection using optical coherence tomography. *American Journal of Ophthalmology*. 2005; 139(1):44-45. <https://doi.org/10.1016/j.ajo.2004.08.069>
  10. Lopes de Faria JM, Russ H, Costa VP. Retinal nerve fiber layer loss in patients with type I Diabetes mellitus without retinopathy. *British Journal of Ophthalmology*. 86(7).
  11. El-Ashry M, Appaswamy S, Deokule S, Pagliarini S. The effect of phacoemulsification cataract surgery on the measurement of retinal nerve fiber layer thickness using optical coherence tomography. *Current Eye Research*. 2006; 31(5):409-413. <https://doi.org/10.1080/02713680600646882>
  12. Aydin A, Wollstein G, Price LL, Fujimoto JG, Schuman JS. Optical coherence tomography assessment of retinal nerve fiber layer thickness changes after glaucoma surgery. *Ophthalmology*. 2003; 110(8):1506-1511. [https://doi.org/10.1016/S0161-6420\(03\)00493-7](https://doi.org/10.1016/S0161-6420(03)00493-7)
  13. Pareja-Estaban J, Tues-Guezala MA, Drake-Casanova P, Depana-Sevilla I. Retinal nerve fiber layer changes after cataract surgery measured by OCT: a pilot study. *Arch Soc Esp Ophthalmol*. 2009; 84(6):305-9.
  14. Dementyev DD, Kourenkov VV, Rodin AS, Fadyken TL, Martinez TED. Retinal nerve fiber layer changes after LASIK evaluated with optical coherence tomography. *Journal of Refractive Surgery*. 2005; 21(5):623-627.
  15. Yamashita T, Uemura A, Kita H, Sakamoto T. Analysis of retinal nerve fiber layer after Indocyanin-Green assisted vitrectomy for idiopathic macular holes. *Ophthalmology*. 2006; 113(2):280-284. <https://doi.org/10.1016/j.ophtha.2005.10.046>
  16. Young- Joon J, Woo-Jin K, II-Hwan S et al. Longitudinal changes in retinal nerve fiber layer thickness after intra vitreal anti vascular endothelial growth factor therapy. *Korean J Ophthalmol*. 2016; 30(2):114-20. <https://doi.org/10.3341/kjo.2016.30.2.114>
  17. Hatata RM, Aly NH, Hassib HM. Comparative study between pre and post intravitreal injection of triamcinolone acetone regarding RNFL thickness in macular edema by OCT. *EC Ophthalmology*. 2017:150-55.
  18. Martinez JM, Ruiz-Calvo A, Saens-Francis F, Reche-Frutos J, Calovo-Gonzalez C, Donate-Lopez J, Garcia-Feijo J. Retinal nerve fiber layer thickness changes in patients with Age-Related macular degeneration treated with intra vitreal Ranibizumab. *Investigative Ophthalmology & Visual Science*. 2012; 53(10):6214-6218. <https://doi.org/10.1167/iovs.12-9875>
  19. Lee YH, Lee JE, Shin YI, Lee KM, Jo YJ, Kim JY. Longitudinal changes in retinal nerve fiber layer thickness after vitrectomy for rhegmatogenous retinal detachment. *Investigative Ophthalmology and Visual Science*. 2010; 53(9):5471-5474. <https://doi.org/10.1167/iovs.12-9782>
  20. Lee SB, Shin YI, Jo YJ, Kim JY. Longitudinal changes in retinal nerve fiber layer thickness after vitrectomy for epiretinal membrane. *Investigative Ophthalmology & Visual Science*. 2014; 55(10):6607-6611. <https://doi.org/10.1167/iovs.14-14196>
  21. Entazari M, Ramezeni A, Yaseri M. Changes in retinal nerve fiber layer thickness after two intravitreal bevacizumab injections for wet type age related macular degeneration. *J Ophthalmic Vis Res*. 2014; 9(4):449-452. <https://doi.org/10.4103/2008-322X.150815>